QUEST DIAGNOSTICS INC Form 8-K May 20, 2011	
SECURITIES AND EXCHANGE COM	MISSION
WASHINGTON, DC 20549	
FORM 8-K	
CURRENT REPORT PURSUANT TO THE SECURITIES EXCHANGE AC	
Date of Report (Date of Earliest Event	Reported): May 17, 2011
Quest Diagnostics Incorporated	
(Exact Name of Registrant as Specified in Its Charter)	
Delaware	
(State or other jurisdiction of Incorporat	ion)
001-12215 (Commission File Number)	16-1387862
	(I.R.S. Employer Identification No.)
Three Giralda Farms	07940
Madison, NJ 07940	0/210

(Address of principal executive offices) (Zip Code)
(973) 520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction a.2. below):
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))

#### Item 5.07. Submission of Matters to a Vote of Security Holders

The Annual Meeting of Shareholders of the Quest Diagnostics Incorporated (the "Company") was held on May 17, 2011.

(b) The following nominees for the office of director were elected for terms expiring at the 2014 Annual Meeting of Shareholders, by the following votes:

For Against Abstain Broker Non-Vote

William F. Buehler 112,629,856 4,869,437 329,644 10,199,580

Daniel C. Stanzione, Ph.D. 112,591,514 4,910,717 326,708 10,199,758

The following persons also continue as directors:

John C. Baldwin, M.D. Jenne K. Britell, Ph.D. Gary M. Pfeiffer Surya N. Mohapatra, Ph.D. Gail R. Wilensky, Ph.D. John B. Ziegler

The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm to audit the financial statements of the Company and its subsidiaries for the fiscal year ending December 31, 2011 was approved by the following votes:

For Against Abstain

125,975,806 1,725,298 327,413

The advisory vote on the compensation of the Company's named executive officers was as follows:

For Against Abstain Broker Non-Vote

108,823,528 7,795,730 1,209,677 10,199,582

The advisory vote on the frequency of future advisory votes on executive compensation was as follows:

3 Years 2 Years 1 Year Abstain Broker Non-Vote

22,916,331 2,148,406 92,299,636 463,753 10,200,391

## Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

May 20, 2011

QUEST DIAGNOSTICS INCORPORATED

By: /s/ William J. O'Shaughnessy, Jr.
William J. O'Shaughnessy, Jr.
Assistant General Counsel and Secretary